Testosterone therapy for women: desire, evidence and safe follow-up

When can testosterone treatment help women?

Testosterone can be considered for selected women with persistent low sexual desire that causes personal distress after a clinical assessment. The strongest evidence concerns postmenopausal women with hypoactive sexual desire disorder, or HSDD. This is a specific sexual-health question, not a recommendation that every person entering menopause needs another hormone. A low blood result alone does not diagnose HSDD or establish that treatment will help. [1], [2], [3]

Start by describing what you want to improve: interest in intimacy, distress about a change in desire, pain, arousal or orgasm. These concerns can overlap, but they are different outcomes. Assessment considers physical symptoms, medicines, mood, relationships and other contributors. You do not need to meet another person's expectation for sexual frequency or tolerate painful contact to deserve care. Your own concern and priorities should guide the discussion. [2], [11]

Authorization depends on the actual product and country. The current UK AndroFeme label has a defined postmenopausal HSDD indication on optimized HRT. That does not authorize every testosterone preparation or every proposed use. Trials and guidance do not establish testosterone as a general treatment for energy, brain fog, muscle gain or prevention of disease. [3], [4]

What decisions belong before a prescription?

The ISSWSH guideline recommends a biopsychosocial assessment, considering interacting biological, psychological and social factors. Treatable contributors should be addressed before or alongside the treatment decision. That does not require you to solve every relationship or health problem alone first; it means the plan should explain which needs it addresses and what else may help. [2]

Bring current hormone products, contraception, antidepressants and other medicines. Explain whether pain, sleep disruption or another symptom makes intimacy difficult. The sexual-health guide develops these distinct care goals, while this guide focuses on the testosterone decision and its boundaries.

Does a low testosterone level identify the cause?

No blood cutoff distinguishes women with and without sexual dysfunction in the Global Consensus statement. HSDD is assessed clinically, not by declaring any low-looking value a deficiency requiring replacement. A person can have difficult low desire for several reasons, and a person with a lower measured value may not be troubled by desire at all. [2], [3]

Testing does have a separate role when testosterone treatment is considered or prescribed. ISSWSH describes baseline total testosterone and sex hormone-binding globulin, or SHBG, and subsequent testing to avoid excessive exposure. It also recommends appropriate liver and lipid assessment. The clinician should explain which tests apply to the chosen product and history, how they will be interpreted and who will review them. [2]

Measurements at female concentrations have technical limitations. The Global Consensus prefers accurate measurement methods and recognizes the practical role of available assays for excluding high baseline or excessive treatment levels. There is no universal high target that guarantees desire. Increasing treatment above the physiological range to overcome high SHBG is not an evidence-supported workaround. Ask how a result changes the clinical plan rather than pursuing a number yourself. [2], [3]

What benefit do randomized studies support?

The 2019 systematic review identified 36 randomized trials involving 8,480 participants. Its pooled findings supported improvements in several sexual-function outcomes in postmenopausal women, including desire, arousal, orgasm and sexual distress. The average difference in satisfying sexual-event frequency was 0.85 compared with placebo or comparator therapy; the Global Consensus describes the treatment effect as roughly one additional satisfying sexual event per month above comparator. [3], [5]

That average is neither a required personal goal nor a guarantee of benefit. Different outcomes were measured with different instruments, and the total review population is not the denominator for every pooled analysis. An improvement in distress may matter even when a simple encounter count is unhelpful. Conversely, a blood value changing without meaningful symptom benefit does not establish successful treatment. [2], [3], [5]

The evidence has limits. Follow-up was insufficient to establish long-term breast or cardiovascular safety, and some trial populations excluded people at higher cardiometabolic risk. Guidance does not extend results automatically to pellets, injections, excessive hormone levels or every compounded preparation. Oral testosterone has unfavorable lipid effects in the reviewed evidence and is not the preferred route in the cited guidance. [2], [3], [5]

Do all guidelines describe the same eligible population?

The 2019 Global Consensus identifies postmenopausal HSDD as the evidence-based indication and considers evidence insufficient for premenopausal women. ISSWSH's 2021 clinical guideline also discusses selected late-reproductive-age women, while acknowledging limited evidence in that group. Neither statement creates a universal recommendation for perimenopausal fatigue or every low-desire concern. These populations and evidence qualifications should stay visible. [2], [3]

The new VA/DoD menopause guideline of August 2026 weakly suggests transdermal testosterone for menopausal sexual dysfunction, especially interest, desire or arousal. Its discussion is broader in wording than the Global Consensus, yet states that most evidence is postmenopausal, that premenopausal evidence is limited and that its review identified no literature specifically addressing perimenopausal treatment. It warns against generalizing the findings to unstudied preparations. [6]

NICE recommends considering testosterone for menopause-associated low sexual desire when HRT alone is ineffective. The actual UK AndroFeme authorization is more product-specific: postmenopausal HSDD on optimized HRT, after psychological, social and other treatable causes are considered. A guideline recommendation and a product label answer related but different questions. Ask the prescriber to identify which supports the proposed use, especially if it falls outside a label. [1], [4]

What does the current UK AndroFeme label actually say?

AndroFeme 10 mg/mL cream has MHRA-authorized UK product information revised July 25, 2025. Its indication is HSDD in postmenopausal women on optimized HRT, following assessment of other relevant factors. NICE's licensing note refers historically to November 2015; it should not be repeated as proof that no current UK women's product exists. Authorization does not establish local stock, public funding or suitability for a particular person. [1], [4]

The following row explains this verified label. It is not a starting prescription for you or instructions for another product.

Concentration, volume and active amount must remain together. A historical patch's delivery rate in micrograms per day is not interchangeable with milligrams applied in a cream. Another gel's pump or sachet can have a different concentration, dispenser and absorption. This guide does not provide improvised fractions of men's products or a pellet or injection regimen. Confirm the exact medicine and measuring instructions with the pharmacist. [2], [4]

The SmPC also addresses concomitant oral conjugated equine estrogen: that treatment should be changed to non-conjugated oral or transdermal estrogen before testosterone is considered. This is a prescriber-led product-specific decision, not a reason to replace your estrogen yourself. Testosterone does not replace the endometrial protection generally needed with systemic estrogen and a uterus. [4], [10]

The same UK label says tibolone and testosterone should not be co-prescribed, and describes closer anticoagulant monitoring when androgen treatment starts or stops. Give the prescriber the complete medicine list so these product-specific considerations can be checked. Do not infer that another medicine’s schedule or an app reminder resolves an interaction. [4]

How should application and transfer precautions be understood?

Use the actual product instructions. The UK AndroFeme label specifies measuring with its graduated applicator, applying to clean dry upper outer thigh or buttock skin and washing hands afterward. It says not to apply to the genitalia or perineum, and to avoid bathing, showering or swimming for at least 4 hours after application. It also advises avoiding cosmetics or sunscreen on the application area and contact between condoms and the product. These details cannot be transferred automatically to another formulation. [4]

Close contact with the application area can transfer testosterone to a partner or child. Wash hands thoroughly with soap and water after each application, cover the area once the cream has dried, and wash the application area with soap and water before anticipated skin-to-skin contact. [4] Ask how to arrange the application safely around caregiving and intimacy rather than assuming a low dose makes precautions unnecessary. Follow the product-specific plan if accidental exposure occurs. [4]

Tell the clinician about skin irritation, difficulty measuring, uncertain instructions or supply changes. The label includes almond oil and other excipients, with relevant sensitivity contraindications. A different cream base or an unmeasured amount is not automatically equivalent or safer. Keep packaging available when asking a pharmacist to resolve a practical problem. [4]

What risks and uncertainties need discussion?

Acne, increased facial or body hair and scalp-hair changes deserve attention. Voice deepening, marked androgenic changes or clitoral enlargement may be irreversible according to the AndroFeme label; prompt assessment is appropriate rather than increasing treatment to seek more benefit. Report unwanted changes even if the most recent blood result was within the laboratory range. A measured concentration is not the entire safety assessment. [2], [4]

The UK AndroFeme label contraindicates use with known, suspected or past breast cancer, known or suspected estrogen-dependent neoplasia, or other conditions consistent with estrogen contraindications. It also contraindicates hypersensitivity to testosterone, tree nuts (almond oil) or its other ingredients. [4] Cardiac, hepatic or renal disease needs particular assessment and monitoring. Trials at physiological exposure do not establish safety for everyone with prior cancer or cardiovascular disease. Ask how the personal history and current label affect the decision. [3], [4]

AndroFeme must not be used during pregnancy, when pregnancy is anticipated, or during breastfeeding. Its label also warns about contact with application sites in these situations and gives washing instructions after exposure. Menopausal HRT is not contraception; if pregnancy remains possible in another treatment context, clarify the separate contraceptive and pregnancy plan with the care team rather than relying on absent periods. [1], [4]

Long-term clinical-trial safety beyond 24 months remains unestablished in the cited product information and guidance. The absence of a serious-event signal in a limited trial dataset is not proof that rare or delayed harms cannot occur. Continued use should remain an informed decision, revisiting benefit, tolerability, changing health and uncertainty. Do not describe treatment as guaranteed breast-safe or heart-protective. [2], [3], [4], [5]

What follow-up and stopping rules apply?

ISSWSH describes checking total testosterone 3–6 weeks after starting treatment and following subsequent changes, with ongoing clinical assessment and measurements once stable. This is guideline monitoring; the actual product can specify its own timing. Testing aims to avoid overuse, not to drive every person to a chosen high value. Ask for the specific dates and the professional responsible for reviewing results. [2]

The AndroFeme label requires clinical assessment and testosterone/SHBG monitoring at 6-month intervals on optimized treatment. It says to discontinue and consider alternatives if there is no improvement after 6 months of continuous optimized therapy. That stopping rule is not permission to ignore troublesome adverse effects until then. The label describes possible benefit after several weeks, but a delay mentioned in research cannot guarantee your response. [4]

At follow-up, describe the meaningful outcome, the actual application and any unwanted effects. If benefit is absent, reassess the diagnosis, contributing factors and other options instead of escalating indefinitely. A new medical concern or significant adverse effect may require earlier review. Ordinary menopause-HRT visits do not replace the separate monitoring plan for testosterone. [1], [2], [4]

Does current research create broader approval or wellness benefits?

The FDA held a September 2026 public workshop about testosterone use in menopausal women, including evidence gaps in sexual function, mood, cognition, musculoskeletal health and long-term safety. Its official event page describes scientific discussion and potential drug development. An event or comment request is not a product approval, and this guide does not treat it as one. [7]

The Global Consensus does not support testosterone for disease prevention or establish benefits for general wellbeing, cognition or musculoskeletal health. Questions about fatigue, concentration, strength or mood deserve appropriate assessment, even when they coexist with low desire. A person's report of feeling better is valuable information for their care, but it does not expand the evidence-based indication or settle long-term safety. [3], [5]

Product access and payment differ between settings. Ask the local clinician and pharmacist to verify authorization, availability and coverage for the exact preparation; use the country guides for access context. Off-label prescribing requires a clear explanation of the proposed use and evidence. The words off-label do not mean every product is identical, and the existence of a licensed option does not make every other formulation licensed.

What do public treatment accounts add?

Two directly accessed Mumsnet discussions from July and September 2026 contain sexual benefit, partial improvement, no meaningful response and concern about acne or hair changes. Some participants describe little effect on energy despite sexual improvement. Others describe several simultaneous treatments, making attribution difficult. These experiences support clear goals and review, not a response rate or a predicted timeline. [8], [9]

The discussions also contain improvised application amounts, site changes and conflicting access statements. Those were not adopted as instructions or current coverage facts. Selected public accounts cannot establish a hormone target or prove a product safe for a particular history. Use the practical question they raise: what changed, what remains difficult and who will help. Use those questions rather than copying the plan.

What is useful to record for the next visit?

Keep the exact product, concentration, prescribed measured amount, application schedule, change dates and agreed test appointments. Choose the concern you hope to improve in your own words; a brief note about interest, distress or comfort can be useful without recording intimate details you do not want to store. Note unwanted skin, hair or voice changes separately. You do not need to count encounters to justify care.

At review, distinguish observation from interpretation. “My interest improved, but acne appeared” describes a mixed response; it does not calculate the next dose. An app can organize the chosen schedule and notes, while the clinician assesses benefit and safety. Doserly tracks the schedule you and your clinician choose. It does not recommend doses. A symptom record cannot diagnose HSDD, establish absorbed exposure or replace laboratory and clinical follow-up.

Common questions about testosterone treatment

Is low desire always a testosterone deficiency?

No. Low desire can reflect pain, medicines, mood, relationships and other factors, and it is not automatically a disorder when it does not trouble you. There is no blood cutoff that diagnoses HSDD or proves the cause of an individual's experience. Explain the change and its personal effect before assuming hormone replacement is needed. The assessment section separates clinical diagnosis from safety testing; useful care can include several approaches rather than a prescription based only on a laboratory value. [2], [3]

Is testosterone always unlicensed for women in the UK?

No. The MHRA-authorized AndroFeme SmPC revised July 25, 2025 has a defined indication for postmenopausal HSDD on optimized HRT after relevant factors are considered. That authorization does not cover all testosterone preparations or all suggested uses, and NICE's November 2015 licensing note is historical context. Ask for the exact product and reason for prescribing it. The product section distinguishes current authorization from broader guidance, availability and payment; none of those can be inferred from a blanket licensing statement. [1], [4]

Does a 5 mg cream application equal a trial patch's delivery rate?

No. Milligrams applied in a measured cream and micrograms delivered by a patch describe different quantities and formulations. Concentration, volume, delivery and absorption need to stay linked to the actual product. A historical trial schedule does not create a conversion for another gel, cream or men's preparation. The product section explains the verified AndroFeme example without prescribing a personal dose; ask the pharmacist to clarify the actual pack and measuring instructions before changing any routine. [2], [4]

Can testosterone replace progesterone in my HRT?

No. Testosterone is not the protective progestogen component generally needed when systemic estrogen is used with a uterus. Its sexual-health purpose and monitoring are different from protecting the uterine lining. If a protective treatment is difficult to tolerate, discuss that problem directly rather than omitting it after testosterone is added. The product section explains why the whole hormone plan remains relevant; a new prescription should identify the role of each component and which clinician manages changes. [4], [10]

Can I apply the cream to genital tissue for more effect?

Do not use that as a workaround. The checked UK AndroFeme label says not to apply to the genitalia or perineum and specifies its own skin sites, measurement and washing precautions. Another person's application habit does not replace these instructions. Persistent dryness or pain may need a separate local assessment and appropriate treatment. The application section explains the product-specific boundaries and transfer concerns; ask the prescriber or pharmacist to resolve uncertainty rather than choosing a new site or unmeasured amount. [4], [11]

Should I continue if the blood result rises but symptoms do not improve?

A higher result alone is not success. Review the actual symptom goal, contributing factors, application and adverse effects with the clinician rather than increasing treatment indefinitely. The AndroFeme label specifies stopping and considering alternatives after 6 months without improvement on continuous optimized therapy, while significant problems can require earlier review. The follow-up section separates the stopping rule from safety testing; the plan should explain what meaningful benefit would look like and who decides the next step. [2], [4]

Are hair or voice changes harmless if my result is normal?

Do not dismiss unwanted changes on that basis. Clinical assessment matters alongside blood testing, and the AndroFeme label warns that some virilizing changes, including voice deepening, can be irreversible. Report the timing, product and actual use promptly so the prescriber can assess the response. The risk section explains why a laboratory range does not capture the entire safety picture; a recent reassuring test is not permission to continue through a significant new effect without advice. [2], [4]

Is testosterone a proven solution for energy, memory or muscle loss?

The cited evidence does not establish those as general treatment indications for women. Randomized evidence is strongest for selected postmenopausal sexual-health concerns, while broader outcomes and long-term safety remain uncertain. Describe fatigue, cognitive difficulty or weakness separately so that appropriate causes and care can be considered. The research section explains why a current workshop or someone's subjective improvement does not create approval or a universal wellness recommendation; distressing symptoms still deserve assessment without an unsupported hormone promise. [3], [5], [7]

Glossary

Terms used in assessment and care.

Perimenopause

The transition toward menopause, with changing ovarian hormone patterns and possible symptoms.

Menopause

Usually identified after 12 months without a period when hormonal contraception does not explain the absence.

Postmenopause

The stage after menopause; symptoms can continue.

Estrogen

A hormone class that includes estradiol.

Estradiol

An estrogen made by the body and used in certain prescribed medicines.

Progesterone

A hormone and one member of the progestogen family.

Progestogen

A family of progesterone-like medicines; some provide uterine protection with estrogen.

Endometrium

The lining inside the uterus.

HRT / MHT

Hormone replacement therapy; menopausal hormone therapy in this guide.

Systemic treatment

Treatment reaching the wider body through the circulation.

Local vaginal estrogen

A low-dose product intended mainly for genitourinary symptoms.

Genitourinary syndrome of menopause

A group of menopause-associated vaginal, sexual and urinary symptoms.

Contraception

A method intended to prevent pregnancy; menopausal HRT is not one.

Testosterone

An androgen; the treatment indication and exposure need product-specific assessment.

Androgen

A hormone acting through androgen-related pathways; not a universal wellness treatment.

HSDD

Hypoactive sexual desire disorder, assessed clinically with low desire and personal distress.

Biopsychosocial assessment

Assessment considering biological, psychological and social contributors together.

SHBG

Sex hormone-binding globulin, relevant to interpreting hormone measurements.

Total testosterone

The measured circulating total; not a diagnostic cutoff for HSDD.

Physiological range

A relevant laboratory reference range used with clinical context, not a target guaranteeing benefit.

Supraphysiological

Above a relevant physiological range, with potential androgenic harms.

Applied amount

Active medicine placed on the skin, distinct from the amount reaching circulation.

Delivery rate

The amount a delivery system releases over a defined time.

Concentration

Active ingredient per defined volume or amount of a formulation.

Virilization

Androgenic changes such as a deeper voice or clitoral enlargement, which may be irreversible.

Hirsutism

Increased coarse hair in androgen-sensitive areas.

Alopecia

Hair loss, assessed with the actual product and clinical history.

Skin transfer

Exposure of another person through contact with an application area.

Indication

The defined treatment purpose in guidance or product authorization.

Off-label use

Use outside the product authorization, requiring a specific clinical explanation.

Satisfying sexual event

A study-specific reported outcome, not a required personal sexual quota.

Confidence interval

An interval expressing uncertainty around an estimated study effect.

Nonresponse

Absence of meaningful benefit requiring clinical reassessment rather than indefinite escalation.

How was this guide researched?

Source selection and limits

Full original ISSWSH 2021 and Global Consensus 2019 statements were reviewed alongside current NICE, the complete UK MHRA AndroFeme SmPC revised July 25, 2025, BMS protection guidance and relevant AUA assessment guidance. The original 2019 review’s publisher abstract/search-indexed text supplies pooled findings; full journal text was not directly retrieved and the overall population is not every outcome denominator. New VA/DoD 2026 original extracted recommendation 26 and discussion were assessed without claiming an exhaustive 191-page appraisal. The FDA September 2026 official event page was checked, without viewing its recordings or inferring approval. Two original public Mumsnet openings/accessible replies were refreshed for mixed experiences, not prescribing or current funding claims.

This is an AI-assisted Doserly editorial guide checked October 3, 2026. No independent clinician review is claimed. Doserly develops a commercial tracking app. Practical record-keeping suggestions are editorial advice, not a validated diagnostic scale or clinical-monitoring system. Material new guidance, labels or safety information trigger earlier source review.

Sources